Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
TAK
TAK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TAK News
Takeda Pharmaceutical Plans 400 Layoffs to Boost Profitability
6d ago
seekingalpha
Rusfertide Shows Significant Improvements in Patient Outcomes for Polycythemia Vera in Pivotal Study
Mar 02 2026
Newsfilter
Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
Feb 28 2026
Yahoo Finance
Mental Health Treatment Market Set for Accelerated Growth
Feb 24 2026
PRnewswire
Mental Health Drug Market Set for Accelerated Growth
Feb 24 2026
Newsfilter
Takeda's Entyvio Phase 3 Trial Shows Positive Results
Feb 20 2026
Benzinga
Positive Phase 3 Results for Vedolizumab in Pediatric Ulcerative Colitis
Feb 19 2026
Newsfilter
FDA Grants Breakthrough Therapy Designation for Rybrevant
Feb 18 2026
Benzinga
Next-Gen CNS Assets Attract Investor Interest
Feb 10 2026
PRnewswire
Next-Gen CNS Assets Attract Investor Interest
Feb 10 2026
Newsfilter
Iambic Partners with Takeda for AI Drug Discovery Collaboration
Feb 09 2026
Benzinga
Iambic Signs $1.7B Multi-Year Deal with Takeda for AI Drug Development
Feb 09 2026
seekingalpha
Takeda (TAK) Q2 2025 Earnings Call Transcript
Feb 05 2026
NASDAQ.COM
Alvotech's AVT80 Biosimilar Study Achieves Success
Feb 05 2026
seekingalpha
Takeda Pharmaceutical Q3 2025 Earnings Report Analysis
Jan 29 2026
Benzinga
Takeda Updates FY2025 Revenue Guidance Amid Cost Discipline
Jan 29 2026
seekingalpha
Show More News
